Under 120 helped after stroke, wasn't proven in diabetes, and the kidneys need watching
Two randomized trials from Brazil tested a systolic target under 120 against under 140 for about four years. After an ischemic stroke the lower target came out ahead; in type 2 diabetes it didn't clearly.
🎧 Listen: Weekly · Nov 16, from 01:47.
The question
SPRINT, the large US trial published in 2015, showed that in people without diabetes, aiming for a systolic under 120 instead of under 140 meant fewer major cardiovascular events and fewer deaths. It left out people with diabetes and people who had had a stroke. In diabetes, ACCORD found no clear benefit from the lower target, and BPROAD, in China, found one.
What was done
Two open-label randomized trials from Brazil, published together in the New England Journal of Medicine, compared a systolic target under 120 with one under 140, with events judged by a committee that didn't know the assignment. OPTIMAL-DIABETES enrolled 9,476 adults aged 50 or older with type 2 diabetes and high cardiovascular risk. OPTIMAL-STROKE enrolled 4,368 adults after an ischemic stroke or transient ischemic attack, once they were stable. Both excluded an eGFR under 20, and both followed patients for a median of about four years. The intensive groups averaged a systolic of about 122, about 13 to 14 points below the standard groups.
What they found
The main outcome was a composite of cardiovascular death, heart attack, stroke, and hospitalization for unstable angina or heart failure.
- Diabetes: 6.7% with the standard target against 6.0% with the lower target, a gap that could have been chance. The authors note the trial was designed to find a larger effect, and that the result is close to ACCORD's.
- After stroke: 13.5% against 10.9%, a difference unlikely to be chance. The benefit was mainly in people who had had a stroke; in the smaller group with a transient ischemic attack the result was unclear. Injurious falls were less common with the lower target, not more.
Why did BPROAD differ? The authors point to the mix of events: strokes made up about 72% of BPROAD's events, and strokes are a bigger share of cardiovascular events in China than in Western populations.
The kidneys
A sustained fall in eGFR of 50% or more, or kidney failure, was more common with the lower target in both trials: 5.7% against 3.7% in the diabetes trial, and 3.9% against 2.2% in the stroke trial, where it wasn't formally tested. Long-term dialysis did not differ in the diabetes trial (21 against 22 patients). The stroke trial's authors note that a definition built on change from baseline can't separate the expected early drop when pressure comes down from true, ongoing loss. Low sodium was more common with the lower target in both trials, and high potassium in the diabetes trial.
Our take
After a stable ischemic stroke, a systolic under 120 is worth aiming for if tolerated, but not in the first days after a stroke. With diabetes alone, under 120 isn't proven, and under 130 remains a reasonable default. Whenever you push lower in a patient with kidney disease, follow the creatinine trend, the potassium and the sodium.
The source: Santo K, Martins E, et al. OPTIMAL-DIABETES. N Engl J Med. Published online November 7, 2026. doi:10.1056/NEJMoa2612922 Read the original
Also discussed:
- OPTIMAL-STROKE. N Engl J Med. Published online November 7, 2026. doi:10.1056/NEJMoa2612924 Link
🎧 Listen: Weekly · Nov 16, from 01:47.
Physician-led, AI-assisted. Dr. Wael Hussein chooses every item NephSpace covers and reviews and edits every story before it is published. The first draft was written in our own words with AI (Claude, by Anthropic) from the full text of the two papers and checked against our reading notes; Dr. Hussein then reviewed and edited it. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Clinicians: read the original before changing practice. See our disclaimer and disclosures. Spotted an error? Tell us.